These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 15135383

  • 1. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression.
    Groetzner J, Kur F, Spelsberg F, Behr J, Frey L, Bittmann I, Vogeser M, Ueberfuhr P, Meiser B, Hatz R, Reichart B, Munich Lung Transplant Group.
    J Heart Lung Transplant; 2004 May; 23(5):632-8. PubMed ID: 15135383
    [Abstract] [Full Text] [Related]

  • 2. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation.
    King-Biggs MB, Dunitz JM, Park SJ, Kay Savik S, Hertz MI.
    Transplantation; 2003 May 15; 75(9):1437-43. PubMed ID: 12792493
    [Abstract] [Full Text] [Related]

  • 3. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
    Albano L, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Blanc AS, Di Giambattista F, Dantal J, RAD A2420 Study Group.
    Transplantation; 2009 Jul 15; 88(1):69-76. PubMed ID: 19584683
    [Abstract] [Full Text] [Related]

  • 4. New-onset diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression.
    Wagner K, Webber SA, Kurland G, Boyle GJ, Miller SA, Cipriani L, Griffith BP, Fricker FJ.
    J Heart Lung Transplant; 1997 Mar 15; 16(3):275-82. PubMed ID: 9087870
    [Abstract] [Full Text] [Related]

  • 5. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun 15; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 6. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.
    Knight RJ, Villa M, Laskey R, Benavides C, Schoenberg L, Welsh M, Kerman RH, Podder H, Van Buren CT, Katz SM, Kahan BD.
    Clin Transplant; 2007 Jun 15; 21(4):460-5. PubMed ID: 17645704
    [Abstract] [Full Text] [Related]

  • 7. Successful use in lung transplantation of an immunosuppressive regimen aimed at reducing target blood levels of sirolimus and tacrolimus.
    Villanueva J, Boukhamseen A, Bhorade SM.
    J Heart Lung Transplant; 2005 Apr 15; 24(4):421-5. PubMed ID: 15797743
    [Abstract] [Full Text] [Related]

  • 8. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
    Toso C, Meeberg GA, Bigam DL, Oberholzer J, Shapiro AM, Gutfreund K, Ma MM, Mason AL, Wong WW, Bain VG, Kneteman NM.
    Transplantation; 2007 May 15; 83(9):1162-8. PubMed ID: 17496530
    [Abstract] [Full Text] [Related]

  • 9. Sirolimus experience in heart transplantation.
    Aranda-Dios A, Lage E, Sobrino JM, Mogollón MV, Guisado A, Cabezón S, Hinojosa R, Hernández A, Ordóñez A.
    Transplant Proc; 2006 Oct 15; 38(8):2547-9. PubMed ID: 17097997
    [Abstract] [Full Text] [Related]

  • 10. Low-dose tacrolimus/sirolimus and steroid withdrawal in heart recipients is highly efficacious.
    Meiser B, Kaczmarek I, Mueller M, Groetzner J, Weis M, Knez A, Stempfle HU, Klauss V, Schmoeckel M, Reichart B, Ueberfuhr P.
    J Heart Lung Transplant; 2007 Jun 15; 26(6):598-603. PubMed ID: 17543783
    [Abstract] [Full Text] [Related]

  • 11. Methotrexate for lung transplant recipients with steroid-resistant acute rejection.
    Cahill BC, O'Rourke MK, Strasburg KA, Savik K, Jessurun J, Bolman RM, Hertz MI.
    J Heart Lung Transplant; 1996 Nov 15; 15(11):1130-7. PubMed ID: 8956122
    [Abstract] [Full Text] [Related]

  • 12. A prospective, pilot study of early corticosteroid cessation in high-immunologic-risk patients: the Cincinnati experience.
    Alloway RR, Hanaway MJ, Trofe J, Boardman R, Rogers CC, Hanaway MJ, Buell JF, Munda R, Alexander JW, Thomas MJ, Roy-Chaudhury P, Cardi M, Woodle ES.
    Transplant Proc; 2005 Mar 15; 37(2):802-3. PubMed ID: 15848537
    [Abstract] [Full Text] [Related]

  • 13. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ.
    Clin Transplant; 2004 Mar 15; 18 Suppl 12():61-6. PubMed ID: 15217410
    [Abstract] [Full Text] [Related]

  • 14. Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection.
    Bhorade SM, Janata K, Vigneswaran WT, Alex CG, Garrity ER.
    J Heart Lung Transplant; 2008 Sep 15; 27(9):990-4. PubMed ID: 18765191
    [Abstract] [Full Text] [Related]

  • 15. Sirolimus in pediatric patients: results in the first 6 months post-renal transplant.
    Hymes LC, Warshaw BL.
    Pediatr Transplant; 2005 Aug 15; 9(4):520-2. PubMed ID: 16048606
    [Abstract] [Full Text] [Related]

  • 16. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R, Cinti P, Lai Q, Poli L, Berloco PB.
    Transpl Immunol; 2008 Nov 15; 20(1-2):3-5. PubMed ID: 18773959
    [Abstract] [Full Text] [Related]

  • 17. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications.
    Dunkelberg JC, Trotter JF, Wachs M, Bak T, Kugelmas M, Steinberg T, Everson GT, Kam I.
    Liver Transpl; 2003 May 15; 9(5):463-8. PubMed ID: 12740787
    [Abstract] [Full Text] [Related]

  • 18. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
    Shenoy S, Hardinger KL, Crippin J, Korenblat K, Lisker-Melman M, Lowell JA, Chapman W.
    Liver Transpl; 2008 Feb 15; 14(2):173-80. PubMed ID: 18236391
    [Abstract] [Full Text] [Related]

  • 19. Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation.
    Ahya VN, McShane PJ, Baz MA, Valentine VG, Arcasoy SM, Love RB, Seethamraju H, Garrity E, Alex CG, Bag R, DeOliveira NC, Vigneswaran WT, Charbeneau J, Krishnan JA, Durazo-Arvizu R, Norwick L, Bhorade S.
    J Heart Lung Transplant; 2011 Feb 15; 30(2):175-81. PubMed ID: 20947384
    [Abstract] [Full Text] [Related]

  • 20. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, Palmer CR, Bradley JA.
    Liver Transpl; 2007 Dec 15; 13(12):1694-702. PubMed ID: 18044728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.